Novartis nabs Merck exec Bruno Strigini to head up oncology business

Bruno Strigini

Novartis ($NVS) wooed one of Merck's ($MRK) top executives to take the helm at its oncology unit. The Swiss drugmaker tapped Bruno Strigini, president of Merck's European and Canadian operations, to take over for Alessandro Riva, who's been interim chief of Oncology Development and Medical Affairs. Riva temporarily replaced Hervé Hoppenot, who jumped ship earlier this year for a CEO job at Novartis development partner Incyte ($INCY). Release